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S282 Poster Session Iproven by CT scan of chest over two winter seasons (two in 2009 and
four in 2010). Median onset of RSV pneumonia in this cohort was 18
months from the date of transplantation (range: 3 months – 8 years).
Patients were diagnosed by positive PCR assay (Three with RSV-A
and 3 with RSV-B). The rapid antigen detection test (Binaxnow, In-
verness Medical) was negative for RSV in all 6 patients. All 6 patients
were sent home from the clinic based on the negative antigen test and
were later admitted to the hospital when the PCR result was available
(range 1-3 days). Patients were treated with aerosolized Ribavirin at
a dose of 2 g. every 8 hours for 3-5 days. No complication was ob-
served other than treatment related bronchospasm that was easily
managed by concomitant inhaled bronchodilators. Most common
complaint was a feeling of claustrophobia associated with the tent
used at the time of treatment delivery. With a median follow up of
4 months (range; 1- 14 months), all patients had shown complete
clinical recovery as well as radiological improvement. There was
no relation between immune-reconstitution to the onset or severity
of the infection.
In conclusion, we recommend universal use of multiplex PCR
based technique for respiratory viral pathogens in stem cell trans-
plant recipients with respiratory symptoms over antigen based detec-
tion test. Early detection and prompt institution of therapy with
inhaled ribavirin may be responsible for 0% mortality in our cohort
compared to published literature.354
SEPSIS MANAGEMENT – HOW SHOULD THE SEPSIS BUNDLE BE UTI-
LIZED IN THE BLOOD AND MARROW TRANSPLANT UNIT?
Rice, J.M. The Ohio State University James Cancer Hospital, Columbus,
OH
In January of 2009, The Ohio State University Medical Center
(OSU) implemented the sepsis bundle guideline. This guideline in-
tended to provide a standard for early recognition of sepsis, provide
initial resuscitative measures, and to provide a pathway for initial
management as well as maintenance of sepsis treatment. All patients
that met initial criteria would have the sepsis bundle implemented.
With initiation of the sepsis bundle on all patients who met crite-
ria, the Blood and Marrow Transplant (BMT) Program at OSU
James Cancer Hospital reviewed their current practice for manage-
ment of these patients. Current practice is to utilize a febrile neutro-
penic pathway rather than the sepsis bundle. As it became apparent
that the sepsis bundle and the febrile neutropenic pathway were
different, a retrospective review of 30 patients was performed from
September 7, 2009 through February 10, 2010. The goal of the
review was to identify patient outcomes in those patients that met
criteria for the sepsis bundle yet were managed via the neutropenic
pathway.
Of the 30 patients reviewed, all met minimum criteria for initia-
tion of the sepsis bundle. All patients were managed via the neutro-
penic pathway rather than the sepsis bundle. In the end, 28 patients
were alive at 30 days with no complications associated with infection.
One patient was discharged to hospice related to graft failure and
multiorgan failure. The other patient developed complications
with respiratory compromise, ARDS, and multiorgan failure and
died as a result associated with ARDS.
This review suggests that BMT patients do not meet normal cri-
teria for implementation of the sepsis bundle. Ongoing discussions
continue to attempt to define specific criteria for implementation
of the sepsis bundle in the bone marrow transplant population.355
RETROSPECTIVE ANALYSIS OF THE EFFICACY OF ANTIEMETIC PROPHY-
LAXIS IN DIFFERENT PREPARATIVE REGIMENS FOR AUTOLOGOUS AND
ALLOGENEIC BONE MARROW TRANSPLANTATION
Duquette, D.1,3,4, Adam, J.-P.1, Goulet, D.1,3,4, Delage, R.2,5 1Centre
Hospitalier Affilie Universitaire de Quebec - Ho^pital Enfant-Jesus,
Quebec, QC, Canada; 2Centre Hospitalier Affilie Universitaire de Quebec
- Ho^pital Enfant-Jesus, Quebec, QC, Canada; 3Universite Laval, Quebec,QC, Canada; 4Centre Hospitalier Affilie Universitaire de Quebec, Quebec,
QC, Canada; 5Universite Laval, Quebec, QC, Canada
Chemotherapy-induced nausea and vomiting (CINV) is of partic-
ular concern for patients undergoing bone marrow transplantation
(BMT) given the highly emetogenic agents used.
We conducted a retrospective observational study to verify the ef-
ficacy of our different prophylactic CINV prevention regimens for
different types of BMTperformed at our center.We looked at 78 au-
tologous and 38 allogeneic BMT patients hospitalised between au-
gust 2007 and july 2009. Patients received our standard antiemetic
prophylaxis tailored to the preparative regimen. Most patients re-
ceived a 5-HT3 antagonist and dexamethasone as prophylaxis and
prochlorperazine for breakthrough nausea. We measured emesis,
nausea and use of breakthrough antiemetics on a daily basis. Results
of the overall absence of emesis, nausea and non-use of breakthrough
antiemetics throughout the entire duration of the BMT process are
given in the following table.
Table 1. Control of nausea and emesis by preparative regimen
BEAM HD-Mel Flu-Cy TBI-Cy Bu-Cy Flu-Bu-ATGAbsence of vomiting 59.6% 29.0% 38.5% 0% 33.3% 66.7%
Absence of nausea 25.5% 6.5% 15.4% 0% 0% 50%
Non-use of
breakthrough
agents25.5% 12.9% 15.4% 0% 0% 50%In the daily evaluations, patients receiving the BEAM regimen and
the high-dose melphalan (HD-Mel) were particularly at risk of eme-
sis immediately following the melphalan. Control of CINV was ap-
proximately 90%before administration ofmelphalan and dropped to
45% on the following days.
The study included only a small number of patients in the alloge-
neic BMT setting. This group was then divided in even smaller co-
horts for each different regimen making it harder to reach
conclusions. However, all groups showed a low incidence of com-
plete control of CINV. The use of high dose cyclophosphamide
has a preparative regimen is associated with very poor nausea con-
trol.
This retrospective case study demonstrates the need to reassess
periodically the effectiveness of our prophylactic regimens for
emesis in the BMT setting and to make the appropriate changes
to improve our supportive care. Our center has changed our pro-
phylactic CINV prevention regimens and aprepitant (Emend)
has been added to some of BMT regimens even if it has not yet
received approval for this indication. Ongoing trials are assessing
its efficacy but early trials have successfully proven its safety. A
second study is planned at our center to evaluate if these modifi-
cations will improve the control of nausea and emesis in our BMT
patients.356
BK VIRUS ASSOCIATED HEMORRHAGIC CYSTITIS IN PEDIATRIC PA-
TIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT
Shakhnovits, M.1, DiMundo, J.1, Pawlowska, A.1, Wolfson, J.1,
Qian, D.2, Sorrell, A.1, Hitt, D.1, Dagis, A.2, Cheng, J.3, Rosenthal, J.1
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Background:Hemorrhagic cystitis (HC) is a severe complication in
pediatric and adult patients (pts) undergoing allogeneic hematopoi-
etic stem cell transplantation (HCT).HC is characterized by urothe-
lial inflammation and painful hematuria which can be microscopic
(Grade I) or macroscopic with blood clots and urinary tract obstruc-
tion (grade II-IV). The incidence of HC in pediatricHCTpts ranges
from about 10% to 20 % and morbidity and mortality is as high as
75% depending on the severity of HC. The etiology of delayed onset
of HC (greater than 2 weeks from conditioning therapy) is multifac-
torial, including damage from conditioning therapy, irradiation,
graft-versus host disease (GVHD), steroids, and viral infection.
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virus (BKV), CMV, and Adenovirus.
Methods:Medical records of 30 pediatric pts who had undergone
allogeneic or autologous HCT at our center between March of
2007 and April of 2010 have been reviewed. Urine of all patients
was sent for quantitative BKV by PCR. BKV positive was consid-
ered as a load of $ 10E6 copies/ml. CMV was monitored quan-
titatively by PCR. Categorical tables were analyzed using
Pearson’s chi-square test and the Cochran-Mantel-Haenszel test.
Tabular and graphical descriptive survival analyses were per-
formed using cumulative incidence methods accounting for com-
peting risks.
Results:Median age at transplant was 12.3 yrs. Nineteen pts had al-
ternative donor HCT: 13 from a matched unrelated donor, 4 from
double cord blood units (CBU) and 2 from a single CBU. Ten
HCT were from matched related donors (MRD), including 1 with
MRD CBU. One pt had an autologous transplant. All pts had re-
ceived a full myeloablative conditioning therapy. Acute GVHD oc-
curred in 28 pts (96.5%); all were treated with methylprednisolone at
a median dose of 60mg daily. Out of 30 patients 10 (33.3%) patients
had HC at a median of 37 days post HCT (range 24 to 73 days). Five
(50%) had grade II HC, two pts (20%) hadmoderate grade III, and 3
(30%) had severe, grade IVHC.HCoccurred in 2 of 12 (17%) BKV-
pts compared with 8 of 18 (44%) BKV+ pts. (p 5 0.11). One of 10
CMV-, BKV- pts (10%) pts had HC; compared to 5 of 15 (33%)
of CMV+, BKV+ pts. (p 5 0.18). The occurrence of severe HC
was correlated with advanced disease state but not with higher ste-
roid doses.
Conclusion: BKV may play a role in HCT. A prospective study is
needed to better identify the role of BKV and CMV in the develop-
ment of HC.357
MEETING THE CHALLENGE: DEVELOPING A MODEL TO CARE FOR AN
ADOLESCENT PATIENT WITH LEUKEMIA AND SEVERE AUTISM
Bain,M.E.,Martin, P.L., Kojis, S., Trout, S.B., Kurtzberg, J. DukeUni-
verstiy Medical Center, Durham, NC; Duke University Medical Center,
Durham, NC; Duke University Medical Center, Durham, NC; Duke
University Medical Center, Durham, NC; Duke University Medical Cen-
ter, Durham, NC
As a Certified Child Life Specialist (CCLS) for the Duke Pediatric
Blood and Marrow Transplant program, one has to be prepared to
provide specialized services to all children. A CCLS has been trained
to incorporate age, diagnosis, developmental level and special needs
in the assessment of each patient. When a teenage girl with second-
ary leukemia and severe autismwas referred for a bonemarrow trans-
plant, all skills were put to the test. As a team, we worked proactively
to ensure a smooth and safe transition from her home hospital to our
transplant facility.
Our initial challenge was to anticipate the needs of this patient be-
fore we had a chance to meet her. A picture of the CCLS was taken
(labeled ‘‘a safe friend’’) and sent to the patient to begin building
a rapport. The CCLS, social worker and nurse coordinator corre-
sponded regularly with the patient’s caregiver before their arrival
to Durham. This dialogue provided our team with information
that helped form her detailed plan of care, and served as a base to
build a trusting relationship.
After learning about the patient’s communication style, photo-
graphs were taken of doctors, nurses, buildings, exam rooms, patient
room, hallway and waiting area, elevators, procedures, medical in-
struments - even mouth care brushes. The pictures were printed
and labeled with detailed descriptions using the five senses, then
mailed to the patient and family. Our goal was to prepare the patient
for a new care team and medical environment.
Our second challenge was to ensure a safe, trusting, and comfort-
able inpatient stay. Because disruptions to routine would often lead
to negative behavior, we provided a structured schedule, consistent
caregivers, and a plan designed to help the patient cope with unex-
pected events. The CCLSworked closely with the staff, psychosocial
team, and quality of life team educating them on the necessity to give
extra preparation time before transitions and/or procedures to allow
for successful cooperation from the patient. In addition, the patientresponded well to incentives (particularly food) to encourage coop-
eration for necessary daily activities.
This experience has provided our transplant team with a deeper
understanding of how to best serve these patients. The knowledge
gained helped us create a model to implement for future transplant
patients we encounter who fall within the autism spectrum.358
MULTIDISCIPLINARY CARE ON AN IN-PATIENT PEDIATRIC BLOOD AND
MARROW TRANSPLANT UNIT THAT DOES NOT INCLUDE RESIDENT PHY-
SICIANS
Kinsella, T.A., Jacobs, J.A., McLean, S.L., Turner, K., Tarin, R.,
Paff, Z.N., Wallace, G., Longhorn, E., Pesok, A., Eckstein, O.,
Baker, A.L., Berger, S., Bessler, L., Davies, S. Cincinnati Children’s
Hospital, Cincinnati, OH
The care of complex pediatric blood and marrow transplant
(BMT) patients requires numerous skilled and complimentary inter-
disciplinary caregivers. Changes in resident hours have altered the
balance of care givers on our team, which has not included residents
for the last five years. Primary bedside care is given by a team of col-
laborative advanced practive nurses (APN), hospitalists and fellows
seven days a week. Additional team members include in-patient
care managers (coordinators), pharmacists, dieticians, chaplains
and social workers. This team covers all aspects of care including
physical, educational, spiritual, cultural and psychosocial needs.
An attending physician oversees the daily intricate planning that is
carried out by the multidisciplinary team, and daily rounds are
conducted at the bedside with parents participating. Each child has
a primary care provider, either an APN, hospitalist or fellow. Presen-
tation of the child on rounds, order writing, lab interpretation, phys-
ical assessments and initiation of the care of the patient are
consistently managed by the primary care provider. Overnight care
is provided by a hospitalist who sleeps in house and works eight con-
secutive nights, providing continuity of care.
This structure, with limited contribution from rotating physicians
(only the fellows are on a ‘‘rotation’’), provides consistent care pro-
viders who are familiar with a patient’s long hospital course and
unit routines. This also provides a familiar face to families and pa-
tients who can often be readmitted.
The nurse care manager facilitates coordination of services such as
discharge planning, home care teaching, ordering home therapies
and supplies, scheduling and coordinating appointments of other
disciplines. The nurse care managers are also the primary educators
of BMT information to our families. The structure of our unit allows
for consistency, continuity of care and can be described as a solid
workforce and a comfort to those families undergoing BMT.359
VORICONAZOLE AS PRIMARY ANTIFUNGAL PROPHYLAXIS IN RECIPI-
ENTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FROM ALTERNATIVE DONORS
Cozzi, J., Basso, A., Lein, J., Saslavsky, J., Saslavsky, M., Pilli, V.
CETRAMOR BMT-Unit, Rosario, Santa Fe, Argentina
Background: Invasive Aspergillosis (IA) has been the leading cause
of death from fungal infections in patients undergoing allogeneic
Haematopoietic Stem Cell Transplantation (HSCT), particularly
from donors other than HLA-identical siblings.Given the high mor-
tality rate associated with IA and our inability to reliably diagnose ac-
tive cases, prophylactic therapy with Voriconazole (VOR) a triazole
with broad-spectrum antifungal activity against several molds, in-
cluding Aspergillus, was instituted as Primary Antifungal Prophy-
laxis (PAF-Px) in this high-risk group of patients.
Methods: from 02/09 to 02/10 nine patients(p) who underwent al-
ternative donor allogeneic HSCT and received VOR as PAF-Px
were studied.The patients received VOR 400 mg PO BID x 1 day,
then 200 mg PO BID.VOR was started the day of HSCT and
planned for 100 days.After day +100 VOR was continued in patients
requering corticosteroids for therapy of graft-versus-host-disease
(GVHD). Age,median(range)30(17-54)years. Male sex: 8 p
